Patients contain genotype AA (rs17209237), CC (rs11745958) and AG (rs6196) showed a better response to GC when their time to reach PDAI 50% and 25%, duration of start of tapering dose, dose to control disease activity, total amount of GC and average dose of GC were significantly lower than remaining groups.